

Remy Gressin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6792243/publications.pdf>

Version: 2024-02-01

88
papers

5,762
citations

136740

32
h-index

76769

74
g-index

89
all docs

89
docs citations

89
times ranked

5878
citing authors

#	ARTICLE	IF	CITATIONS
1	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
2	Clinical and biologic features of CD4+CD56+ malignancies. <i>Blood</i> , 2002, 99, 1556-1563.	0.6	404
3	Identification of a leukemic counterpart of the plasmacytoid dendritic cells. <i>Blood</i> , 2001, 97, 3210-3217.	0.6	356
4	In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. <i>Blood</i> , 2003, 101, 949-954.	0.6	333
5	Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support. <i>New England Journal of Medicine</i> , 2004, 350, 1287-1295.	13.9	324
6	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	13.9	313
7	Recurrent Mutations of <i>MYD88</i> and <i>TBL1XR1</i> in Primary Central Nervous System Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 5203-5211.	3.2	210
8	High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. <i>Blood</i> , 2005, 105, 3817-3823.	0.6	176
9	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e251-e259.	2.2	164
10	Non-Hodgkin's lymphomas with t(11;14)(q13;q32): a subset of mantle zone/intermediate lymphocytic lymphoma?. <i>British Journal of Haematology</i> , 1991, 77, 346-353.	1.2	154
11	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. <i>Blood</i> , 2009, 113, 995-1001.	0.6	144
12	Upfront VIP-reinforced ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. <i>British Journal of Haematology</i> , 2010, 151, 159-166.	1.2	137
13	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016, 18, 1297-1303.	0.6	135
14	Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 104-110.	0.8	134
15	Management and outcome of primary CNS lymphoma in the modern era. <i>Neurology</i> , 2020, 94, e1027-e1039.	1.5	125
16	BET Family Protein BRD4: An Emerging Actor in NF- κ B Signaling in Inflammation and Cancer. <i>Biomedicines</i> , 2018, 6, 16.	1.4	123
17	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 174-181.	0.6	121
18	Portal Vein Thrombosis following Splenectomy for Hematologic Disease: Prospective Study with Doppler Color Flow Imaging. <i>World Journal of Surgery</i> , 1998, 22, 1082-1086.	0.8	119

#	ARTICLE	IF	CITATIONS
19	L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. <i>Annals of Oncology</i> , 2009, 20, 110-116.	0.6	111
20	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , 2011, 96, 1128-1135.	1.7	99
21	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. <i>Haematologica</i> , 2012, 97, 1085-1091.	1.7	94
22	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2018, 19, 1449-1458.	5.1	93
23	Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1633-1642.	3.3	76
24	Transplantation in Waldenstrom's macroglobulinemia—the French experience. <i>Seminars in Oncology</i> , 2003, 30, 291-296.	0.8	68
25	Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. <i>Haematologica</i> , 2010, 95, 1865-1872.	1.7	68
26	Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. <i>Blood</i> , 2010, 115, 2420-2429.	0.6	67
27	Identification of a novel <scp>BET</scp> bromodomain inhibitor—sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. <i>EMBO Molecular Medicine</i> , 2013, 5, 1180-1195.	3.3	64
28	Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. <i>Blood</i> , 2016, 127, 3040-3053.	0.6	60
29	Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. <i>European Journal of Dermatology</i> , 2010, 20, 016-023.	0.3	54
30	Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. <i>Annals of Oncology</i> , 2012, 23, 1555-1561.	0.6	39
31	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. <i>Haematologica</i> , 2019, 104, e562-e565.	1.7	38
32	A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, 138-146.	1.7	37
33	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. <i>Haematologica</i> , 2010, 95, 1350-1357.	1.7	36
34	1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma. <i>EMBO Molecular Medicine</i> , 2010, 2, 159-171.	3.3	33
35	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	2.2	33
36	Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from Lymphoma Study Association (LYSA) centers. <i>American Journal of Hematology</i> , 2018, 93, 729-735.	2.0	31

#	ARTICLE	IF	CITATIONS
37	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. <i>Haematologica</i> , 2020, 105, e33-e36.	1.7	31
38	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3692-3698.	0.8	31
39	Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. <i>Haematologica</i> , 2015, 100, 1199-1206.	1.7	30
40	Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. <i>Neuro-Oncology</i> , 2016, 19, now238.	0.6	30
41	Quality control for the validation of extracorporeal photopheresis process using the Vibertâ€“Lourmat UV-A irradiationâ€™s system. <i>Transfusion and Apheresis Science</i> , 2003, 28, 63-70.	0.5	26
42	Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. <i>European Journal of Cancer</i> , 2000, 36, 2360-2367.	1.3	24
43	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. <i>Annals of Oncology</i> , 2012, 23, 2687-2695.	0.6	23
44	Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2013, 2, 4.	2.0	23
45	Autotumour reactive T-cell clones among tumour-infiltrating T lymphocytes in B-cell non-Hodgkin's lymphomas. <i>British Journal of Haematology</i> , 1995, 90, 837-843.	1.2	22
46	Composite splenic marginal zone lymphoma and mantle cell lymphoma arising from 2 independent B-cell clones. <i>Human Pathology</i> , 2007, 38, 660-667.	1.1	21
47	Accurate detection of the tumor clone in peripheral T-cell lymphoma biopsies by flow cytometric analysis of TCR-V β 2 repertoire. <i>Modern Pathology</i> , 2012, 25, 1246-1257.	2.9	21
48	Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkinâ€™s lymphoma. <i>Leukemia</i> , 1999, 13, 1428-1433.	3.3	20
49	Silicone lymphadenopathy mimicking a lymphoma in a patient with a metatarsophalangeal joint prosthesis. <i>Journal of Clinical Pathology</i> , 2000, 53, 549-551.	1.0	20
50	Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2986-2988.	0.6	20
51	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. <i>Bone Marrow Transplantation</i> , 2020, 55, 1076-1084.	1.3	20
52	Long-term follow-up of a randomized trial of fludarabineâ€™mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies. <i>Annals of Oncology</i> , 2005, 16, 466-472.	0.6	17
53	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014, 93, 233-242.	0.8	17
54	Deletion 7q in B-Cell Low-Grade Lymphoid Malignancies. <i>Cancer Genetics and Cytogenetics</i> , 1999, 109, 21-28.	1.0	16

#	ARTICLE	IF	CITATIONS
55	Front-line High-Dose Chemotherapy with Rituximab Showed Excellent Long-Term Survival in Adults with Aggressive Large B-Cell Lymphoma: Final Results of a Phase II GOELAMS Study. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 672-677.	2.0	15
56	A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 2803-2803.	0.6	15
57	Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas. <i>Experimental Hematology</i> , 1999, 27, 1185-1193.	0.2	14
58	Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sjögren's syndrome. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 343-346.	1.5	14
59	Cloned <i>IGH VDJ</i> targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang. <i>British Journal of Haematology</i> , 2012, 158, 186-197.	1.2	13
60	Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. <i>Blood</i> , 2012, 120, 152-152.	0.6	13
61	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. <i>British Journal of Haematology</i> , 2013, 162, 240-249.	1.2	12
62	Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 629-635.	1.2	12
63	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. <i>Bone Marrow Transplantation</i> , 2022, 57, 966-974.	1.3	12
64	Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia. <i>Annals of Oncology</i> , 2012, 23, 2386-2390.	0.6	11
65	No Benefit of First-Line Rituximab (R) - High-Dose Therapy (R-HDT) Over R-CHOP14 for Young Adults with Diffuse Large B-Cell Lymphoma. Preliminary Results of the GOELAMS 075 Prospective Multicentre Randomized Trial. <i>Blood</i> , 2010, 116, 685-685.	0.6	11
66	Differentiation of anti-tumour cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non-Hodgkin's lymphomas. <i>British Journal of Haematology</i> , 2002, 119, 425-431.	1.2	10
67	Title is missing!. <i>Annals of Oncology</i> , 1997, 8, 103-106.	0.6	10
68	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y Epratuzumab Tetraxetan Following R-CHOP In Elderly DLBCL Patients. <i>Blood</i> , 2010, 116, 2875-2875.	0.6	10
69	Growth Modulation of Freshly Isolated Non-Hodgkin's B-Lymphoma Cells Induced by Various Cytokines and All-Trans-Retinoic-Acid. <i>Leukemia and Lymphoma</i> , 1997, 25, 169-178.	0.6	8
70	Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review. <i>Leukemia and Lymphoma</i> , 2008, 49, 1762-1768.	0.6	8
71	Prospective Randomized Study Comparing MEMID with a Chop-Like Regimen in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Oncology</i> , 2005, 69, 19-26.	0.9	7
72	Arsenic trioxide rewires mantle cell lymphoma response to Abatezomib. <i>Cancer Medicine</i> , 2015, 4, 1754-1766.	1.3	7

#	ARTICLE	IF	CITATIONS
73	Treatment of the elderly patient with mantle cell lymphoma. Hematology American Society of Hematology Education Program, 2016, 2016, 425-431.	0.9	6
74	Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. Leukemia and Lymphoma, 2016, 57, 1149-1153.	0.6	6
75	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. Bone Marrow Transplantation, 2021, 56, 1700-1709.	1.3	6
76	CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL. Cancers, 2021, 13, 5900.	1.7	6
77	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. Blood, 2012, 120, 906-906.	0.6	5
78	Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. Experimental Cell Research, 2009, 315, 3281-3293.	1.2	4
79	Multifocal polyclonal Epstein-Barr virus-associated B-cell lymphoproliferative disorder secondary to azathioprine therapy successfully treated with rituximab. Leukemia and Lymphoma, 2010, 51, 174-177.	0.6	4
80	The Ribvd Regimen (Rituximab IV, Bendamustine IV, Velcade SC, Dexamethasone IV) Offers a High Complete Response Rate In Elderly Patients With Untreated Mantle Cell Lymphoma. Preliminary Results Of The Lysa Trial - Lymphome Du Manteau 2010 SA - Blood, 2013, 122, 370-370.	0.6	4
81	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. Bone Marrow Transplantation, 2022, 57, 627-632.	1.3	4
82	Phenotypic, morphologic changes and Ig secretion induced on B-NHL cells <i>in vitro</i> by interferon alpha and all-trans-retinoic acid: possible progression toward a more differentiated state. European Journal of Haematology, 1998, 61, 84-92.	1.1	3
83	Les lymphomes agressifs. Medecine Nucleaire, 2009, 33, 478-481.	0.2	3
84	Severe excessive daytime sleepiness induced by hydroxyurea. Fundamental and Clinical Pharmacology, 2017, 31, 367-368.	1.0	3
85	High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial. Blood, 2010, 116, 1758-1758.	0.6	2
86	Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP-treated DLBCL. HemaSphere, 2021, 5, e598.	1.2	1
87	Diagnostic et nosologie des lymphomes au sein des hémopathies. Medecine Nucleaire, 2009, 33, 482-485.	0.2	0
88	GMCLI, Goelams Mantle Cell Lymphoma Index, a New Prognostic Index of Survival for MCL Patients Treated with VAD-C and Autologous PBSCT.. Blood, 2006, 108, 2447-2447.	0.6	0